BIRC5 and acute myeloid leukemia: Although survivin was listed as one of the top 15 prioritised antigens by virtue of its therapeutic function, immunogenicity, specificity and oncogenicity among other features [23], it has been shown to be downregulated in both chronic myeloid leukemia (CML) [24] and AML-derived leukaemic stem cells (LSCs) [25].